FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) and eGFR chronic...
Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALLPALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) --...
New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life (QoL) when compared to baseline...
Experienced Health Care Industry Investor with Track Record of Identifying Innovative Life Science Companies with High Growth PotentialSAN DIEGO and...
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and...
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA...
TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency...
Agreements provide opportunity for improved revenue and cash flow generation in MarylandMINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Goodness Growth...
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001,...
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in...
MARVEL™ is Globus Medical’s second major release this year in the pediatric scoliosis spaceAUDUBON, Pa., July 31, 2023 (GLOBE NEWSWIRE)...
89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their...
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million2, and long-term deposit at €9.3 million3 as of...
Raises 2023 GuidanceNASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), today announced financial and operating results for the second quarter ended June...
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition...
New U.S. patent provides intellectual property (IP) protection until December 2040, and may qualify for term extension beyond 2040There are...
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no...
SCOTTSDALE, Ariz., July 03, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that...
ATLANTA, GA, June 28, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (NYSE American: RHE) (NYSE American: RHE-PA) (“RHE” or...
LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”)...